hypoxia-responsive CEA-targeted CAR T-cells

Hypoxia-responsive CEA-targeted CAR T-cells are a novel form of chimeric antigen receptor (CAR) T-cell therapy engineered to selectively target carcinoembryonic antigen (CEA)-expressing tumor cells in the hypoxic microenvironment characteristic of many solid tumors. The therapy utilizes a genetic construct where the expression of the anti-CEA CAR is regulated by hypoxia-responsive elements, ensuring that high levels of the receptor are expressed primarily under low oxygen conditions found within tumors. This design aims to minimize off-tumor toxicity and enhance safety by limiting activity in normal tissues with normoxic conditions. Preclinical studies have shown that these modified T-cells exhibit reduced exhaustion, enhanced metabolic fitness, increased proliferation under hypoxic stress, and improved antitumor efficacy compared to conventional (constitutively active) anti-CEA CAR-T cells. Early-phase clinical trials have demonstrated promising antitumor activity and manageable safety profiles in patients with relapsed or refractory solid tumors expressing CEA[1][2][3][4].

Other names

hypoxia-inducible CEA-targeted CAR T-cells5H1P-CEA CAR-T cells